Skip to main content
Top
Published in:

Open Access 01-12-2024 | Human Papillomavirus | Research

Validity of Mehrviru® and Sacace® in molecular detection of HPV: a latent class analysis

Authors: Hadi Nowrozi, Fahimeh Ramezani Tehrani, Mahmood Soleimanidodaran, Dariush Hamedi, Masoud Solaymani-Dodaran

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Valid diagnostic tests for human papillomavirus (HPV) detection are crucial to identify individuals at high risk of cervical cancer. We assessed and compared the validity of Mehrviru HPV genotyping and Sacace (HPV Genotypes 14 Real-TM Quant) for molecular detection of 14 high-risk human papillomaviruses.

Methods

We used three HPV test results to identify HPV-positive individuals (14 high-risk genotypes) in a specialist gynecology clinic. The HPV test results were collected using Mehrviru®, Sacace®, and a third kit from the clinical diagnostic laboratory. We used Latent class analysis to determine the actual status of HPV infection in study participants. The sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, Youden, and area under the ROC curve indices of each diagnostic kit and their 95% confidence intervals were calculated. The agreement between the Mehrviru and Sacace kits was determined using the Kappa statistic.

Results

We examined 117 women at high risk of HPV infection. The mean age (SD) was 37.2 (9.1). According to LCA, 28.6% of participants had an HPV infection. The sensitivity and specificity (95% CI) of the Mehrviru were 90.8% (73.7-97.2%) and 90.9% (82.1-95.6%), and corresponding figures for Sacace were 92.0% (72.3-98.1%) and 97.4% (90.2-99.3%). The kappa index between the Mehrviru and Sacace kits was 69.7% (55.6-83.9%). The area under the ROC curve for Mehrviru and Sacace test were 91.4% (85.7-97.1%) and 94.4% (89.3-99.5%).

Conclusions

There is an excellent agreement between Mehrviru and Sacace test results, and the diagnostic accuracy indices were similar.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. <ArticleTitle Language=“En”>Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. <ArticleTitle Language=“En”>Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed
2.
go back to reference Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S, editors. Human papillomaviruses in urological malignancies: a critical assessment. Urologic Oncology: Seminars and Original Investigations; 2014. Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S, editors. Human papillomaviruses in urological malignancies: a critical assessment. Urologic Oncology: Seminars and Original Investigations; 2014.
3.
go back to reference Rao H-L, Chen J-W, Li M, Xiao Y-B, Fu J, Zeng Y-X, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS ONE. 2012;7(1):e30806.CrossRefPubMedPubMedCentral Rao H-L, Chen J-W, Li M, Xiao Y-B, Fu J, Zeng Y-X, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS ONE. 2012;7(1):e30806.CrossRefPubMedPubMedCentral
4.
go back to reference Humans IWGotEoCRt. Biological agents. 100 B. A review of human carcinogens: Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2012;100:255–313. Humans IWGotEoCRt. Biological agents. 100 B. A review of human carcinogens: Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2012;100:255–313.
5.
go back to reference Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1–2):224–31.CrossRefPubMed Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1–2):224–31.CrossRefPubMed
6.
go back to reference Chacón J, Sanz I, Rubio MD, de la Morena ML, Díaz E, Mateos ML, et al. Detection and genotyping of high-risk human papillomavirus in cervical specimens. Enferm Infecc Microbiol Clin. 2007;25(5):311–6.CrossRefPubMed Chacón J, Sanz I, Rubio MD, de la Morena ML, Díaz E, Mateos ML, et al. Detection and genotyping of high-risk human papillomavirus in cervical specimens. Enferm Infecc Microbiol Clin. 2007;25(5):311–6.CrossRefPubMed
7.
go back to reference Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E, et al. Human papillomavirus typing of invasive cervical cancers in Italy. Infect Agents Cancer. 2006;1(1):1–3. Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E, et al. Human papillomavirus typing of invasive cervical cancers in Italy. Infect Agents Cancer. 2006;1(1):1–3.
8.
go back to reference Munoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278–85.CrossRefPubMed Munoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278–85.CrossRefPubMed
9.
go back to reference Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, et al. Prevalence and genotype distribution of HPV infection in China: analysis of 51,345 HPV genotyping results from China’s largest CAP certified laboratory. J Cancer. 2016;7(9):1037.CrossRefPubMedPubMedCentral Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, et al. Prevalence and genotype distribution of HPV infection in China: analysis of 51,345 HPV genotyping results from China’s largest CAP certified laboratory. J Cancer. 2016;7(9):1037.CrossRefPubMedPubMedCentral
10.
go back to reference Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.CrossRefPubMed Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.CrossRefPubMed
11.
go back to reference Castellsagué X, Díaz M, De Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98(5):303–15.CrossRefPubMed Castellsagué X, Díaz M, De Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98(5):303–15.CrossRefPubMed
12.
go back to reference Arroyo Mühr LS, Eklund C, Lagheden C, Forslund O, Robertsson KD, Dillner J. Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study. J Clin Virol. 2022;154:105237.CrossRefPubMedPubMedCentral Arroyo Mühr LS, Eklund C, Lagheden C, Forslund O, Robertsson KD, Dillner J. Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study. J Clin Virol. 2022;154:105237.CrossRefPubMedPubMedCentral
13.
go back to reference Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88–99.CrossRefPubMed Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30:F88–99.CrossRefPubMed
14.
go back to reference Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30:F100–6.CrossRefPubMed Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30:F100–6.CrossRefPubMed
15.
go back to reference Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev anti-infective therapy. 2010;8(10):1139–62.CrossRefPubMed Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev anti-infective therapy. 2010;8(10):1139–62.CrossRefPubMed
16.
go back to reference Hagenaars JA, McCutcheon AL. Applied latent class analysis. Cambridge University Press; 2002. Hagenaars JA, McCutcheon AL. Applied latent class analysis. Cambridge University Press; 2002.
17.
go back to reference Garrett ES, Eaton WW, Zeger S. Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach. Stat Med. 2002;21(9):1289–307.CrossRefPubMed Garrett ES, Eaton WW, Zeger S. Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach. Stat Med. 2002;21(9):1289–307.CrossRefPubMed
18.
go back to reference Sundaramurthy R, Dhodapkar R, Kaliaperumal S, Harish BN. Investigational approach to adenoviral conjunctivitis: comparison of three diagnostic tests using a Bayesian latent class model. J Infect Developing Ctries. 2018;12(01):043–51.CrossRef Sundaramurthy R, Dhodapkar R, Kaliaperumal S, Harish BN. Investigational approach to adenoviral conjunctivitis: comparison of three diagnostic tests using a Bayesian latent class model. J Infect Developing Ctries. 2018;12(01):043–51.CrossRef
19.
go back to reference Fowler JR, Cipolli W, Hanson T. A comparison of three diagnostic tests for carpal tunnel syndrome using latent class analysis. JBJS. 2015;97(23):1958–61.CrossRef Fowler JR, Cipolli W, Hanson T. A comparison of three diagnostic tests for carpal tunnel syndrome using latent class analysis. JBJS. 2015;97(23):1958–61.CrossRef
20.
go back to reference Thaler MA, Bietenbeck A, Yin M-X, Steigerwald U, Holmes AB, Lindhoff-Last E, et al. Evaluation of antiphospholipid antibody assays using latent class analysis to address the lack of a reference standard. Clin Chem Lab Med (CCLM). 2016;54(12):1929–37.CrossRefPubMed Thaler MA, Bietenbeck A, Yin M-X, Steigerwald U, Holmes AB, Lindhoff-Last E, et al. Evaluation of antiphospholipid antibody assays using latent class analysis to address the lack of a reference standard. Clin Chem Lab Med (CCLM). 2016;54(12):1929–37.CrossRefPubMed
22.
go back to reference Qaderi K, Mirmolaei ST, Geranmayeh M, Sheikh Hasani S, Farnam F. Iranian women’s psychological responses to positive HPV test result: a qualitative study. BMC Womens Health. 2021;21(1):1–11.CrossRef Qaderi K, Mirmolaei ST, Geranmayeh M, Sheikh Hasani S, Farnam F. Iranian women’s psychological responses to positive HPV test result: a qualitative study. BMC Womens Health. 2021;21(1):1–11.CrossRef
23.
go back to reference Korfage IJ, van Ballegooijen M, Huveneers H, Essink-Bot M-L. Anxiety and borderline PAP smear results. Eur J Cancer. 2010;46(1):134–41.CrossRefPubMed Korfage IJ, van Ballegooijen M, Huveneers H, Essink-Bot M-L. Anxiety and borderline PAP smear results. Eur J Cancer. 2010;46(1):134–41.CrossRefPubMed
24.
go back to reference Macios A, Nowakowski A. False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health. Diagnostics (Basel). 2022;12(6). Macios A, Nowakowski A. False Negative Results in Cervical Cancer Screening-Risks, Reasons and Implications for Clinical Practice and Public Health. Diagnostics (Basel). 2022;12(6).
25.
go back to reference Teoh D, Hultman G, DeKam M, Isaksson Vogel R, Downs LS Jr., Geller MA, et al. Excess Cost of Cervical Cancer Screening Beyond Recommended Screening Ages or After Hysterectomy in a Single Institution. J Low Genit Tract Dis. 2018;22(3):184–8.CrossRefPubMedPubMedCentral Teoh D, Hultman G, DeKam M, Isaksson Vogel R, Downs LS Jr., Geller MA, et al. Excess Cost of Cervical Cancer Screening Beyond Recommended Screening Ages or After Hysterectomy in a Single Institution. J Low Genit Tract Dis. 2018;22(3):184–8.CrossRefPubMedPubMedCentral
26.
go back to reference Muthén B, Muthén LK. Integrating person-centered and variable‐centered analyses: Growth mixture modeling with latent trajectory classes. Alcoholism: Clin experimental Res. 2000;24(6):882–91.CrossRef Muthén B, Muthén LK. Integrating person-centered and variable‐centered analyses: Growth mixture modeling with latent trajectory classes. Alcoholism: Clin experimental Res. 2000;24(6):882–91.CrossRef
Metadata
Title
Validity of Mehrviru® and Sacace® in molecular detection of HPV: a latent class analysis
Authors
Hadi Nowrozi
Fahimeh Ramezani Tehrani
Mahmood Soleimanidodaran
Dariush Hamedi
Masoud Solaymani-Dodaran
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-10121-9

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
 

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Register your interest now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more